Overview: Expansion of clinical programs to investigate hMSC-EVs, including exosomes, requires maximizing EV/exosome productivity in a scalable manufacturing platform. EV productivity is determined during the upstream process by the number ... More
Listen to this Blog: Your browser does not support audio. An Interview with Amy Permenter, Senior Client Success Representative Carson: Fellow Roosters and other “avian-sapiens” in our flock… Here ... More
Listen to this Blog: Your browser does not support audio. Part IV of a Series on CQAs & CPPs << Read Part I Since 2011, clinical translation centers and ... More
Listen to this Blog: Your browser does not support audio. To many biologists and immunologists, the notion that T cells and mesenchymal stromal/stem cells (MSCs) can be compared in ... More
Listen to this Blog: Your browser does not support audio. What is a Therapeutic Dose for EVs? Extracellular vesicles derived from MSCs (MSC-EVs) are promising therapeutic candidates that have ... More
Carson: I’m here with Joe Candiello, who is Senior Product Manager at RoosterBio. I’m very pleased to have you here as the introductory subject of our “Life at the Roost” ... More
Listen to this Blog: Your browser does not support audio. Let’s agree — Healthcare innovations require infrastructure, but the infrastructure to support the innovations of cell therapy needs shoring ... More
Listen to this Blog: Your browser does not support audio. A Brief History of Cell-Derived Particles Extracellular Vesicle (EV) Figure 1. Illustration of an extracellular vesicle. RNAs = ribonucleic ... More
“So once you know what the question actually is, you’ll know what the answer means.” -Douglas Adams, Author of Hitchhiker’s Guide to the Galaxy [1] From Answers to ... More
Dr. Ibrahim Ozbolat, a familiar name and known figure in the world of bioprinting and tissue engineering, is embarking onto a journey to develop an intraoperative composite tissue bioprinting technique ... More
